US4987086A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for analysis of subpopulations of cells
Assignee: Becton Dickinson and Co
•
Filing: 1987-11-30
•
Granted: 1991-01-22
•
Expires: 2007-11-30
Abstract
Abstract A method and kit for determination of subsets of leukocytes utilizing flow cytometry analysis techniques.
Inventors
- 👤 Jeanne M. Brosnan
- 👤 Kenneth A. Ault
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 22:43
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/569; G01N33/56966; G01N33/56972; G01N15/00; G01N15/10; G01N15/14; G01N15/1456; Y; Y10; Y10S; Y10S436/00; Y10S436/805; Y10S436/807; Y10S436/808; Y10T; Y10T436/00; Y10T436/13
Claims Analysis
Total Claims: 27
Claim 1
Independent Claim
342 words
In a method of identifying and enumerating two or more subpopulations of a population of cells of interest in a whole blood sample by means of flow cytometry, wherein the sample has been split into three aliquots, wherein the first aliquot is labeled with a first fluorescently labeled monoclonal antibody and a second fluorescently labeled monoclonal antibody that react differentially with all of populations of cells in such a manner as to separate the populations from one another when both antibodies are used, the second aliquot is labeled with a first fluorescently labeled irrelevant control and a second fluorescently labeled irrelevant control, and the third aliquot is labeled with a third fluorescently labeled monoclonal antibody and a fourth fluorescently labeled monoclonal antibody that are different from the first and second monoclonal antibodies and react differentially with the cells of the subpopulations of interest, and wherein the fluorescent label on the first antibody, first control and third antibody are the same and the fluorescent label on the second antibody, second control and fourth antibody are the same but which has an emission spectra different from the other fluorescent label, the improvement comprising the steps of: (a) establishing a cell population gate that will contain the maximum number of all cells in the population of interest with a minimum level of contamination from other cell populations by analyzing the first aliquot and selecting the gate based upon an analysis SSC and FL2 to set the SSC boundary and FSC and FL1 to set the FSC boundary and calculating the percentage of contamination of other populations of cells within the gate; (b) establishing fluorescence markers for each of the fluorescence labels used by analyzing the second aliquot applying the gate from step (a) and selecting the markers based upon fluorescence emissions and calculating the percentage of non-specific staining in the sample; and (c) analyzing the third aliquot using the gate and percent contamination from step (a) and the fluorescence markers and percent non-specific staining from step (b) to identify and enumerate cells in each subpopulation.
Claim 2
Dependent Claim
342 words
In a method of identifying and enumerating two or more subpopulations of a population of cells of interest in a whole blood sample by means of flow cytometry, wherein the sample has been split into three aliquots, wherein the first aliquot is labeled with a first fluorescently labeled monoclonal antibody and a second fluorescently labeled monoclonal antibody that react differentially with all of populations of cells in such a manner as to separate the populations from one another when both antibodies are used, the second aliquot is labeled with a first fluorescently labeled irrelevant control and a second fluorescently labeled irrelevant control, and the third aliquot is labeled with a third fluorescently labeled monoclonal antibody and a fourth fluorescently labeled monoclonal antibody that are different from the first and second monoclonal antibodies and react differentially with the cells of the subpopulations of interest, and wherein the fluorescent label on the first antibody, first control and third antibody are the same and the fluorescent label on the second antibody, second control and fourth antibody are the same but which has an emission spectra different from the other fluorescent label, the improvement comprising the steps of: (a) establishing a cell population gate that will contain the maximum number of all cells in the population of interest with a minimum level of contamination from other cell populations by analyzing the first aliquot and selecting the gate based upon an analysis SSC and FL2 to set the SSC boundary and FSC and FL1 to set the FSC boundary and calculating the percentage of contamination of other populations of cells within the gate; (b) establishing fluorescence markers for each of the fluorescence labels used by analyzing the second aliquot applying the gate from step (a) and selecting the markers based upon fluorescence emissions and calculating the percentage of non-specific staining in the sample; and (c) analyzing the third aliquot using the gate and percent contamination from step (a) and the fluorescence markers and percent non-specific staining from step (b) to identify and enumerate cells in each subpopulation.
Claim 3
Dependent Claim
25 words
The method of claim 1 wherein the cell population gate of step (a) includes greater than 98% of all cells in the population of interest.
Claim 4
Dependent Claim
16 words
A method in accordance with claim 1 wherein erythrocytes are removed from the whole blood sample.
Claim 5
Dependent Claim
14 words
A method in accordance with claim 1 wherein said population of interest comprises lymphocytes.
Claim 6
Dependent Claim
27 words
A method in accordance with claim 1 wherein said first monoclonal antibody reacts with substantially all leukocytes and said second monoclonal antibody reacts with substantially all monocytes.
Claim 7
Dependent Claim
27 words
A method in accordance with claim 4 wherein said third monoclonal antibody reacts with substantially all T-cells and said fourth monoclonal antibody reacts with substantially all B-cells.
Claim 8
Dependent Claim
27 words
A method in accordance with claim 5 wherein said third monoclonal antibody reacts with substantially all T-cells and said fourth monoclonal antibody reacts with substantially all B-cells.
Claim 9
Dependent Claim
32 words
A method in accordance with claim 4 wherein said third monoclonal antibody reacts with substantially all T-cells and said fourth monoclonal antibody reacts with at least one activation antigen expressed by T-cells.
Claim 10
Dependent Claim
32 words
A method in accordance with claim 5 wherein said third monoclonal antibody reacts with substantially all T-cells and said fourth monoclonal antibody reacts with at least one activation antigen expressed by T-cells.
Claim 11
Dependent Claim
34 words
A method in accordance with claim 4 wherein said third monoclonal antibody reacts with substantially all CD4 bearing cells and said fourth monoclonal antibody reacts with substantially all cells expressing the Leu 8 antigen.
Claim 12
Dependent Claim
34 words
A method in accordance with claim 5 wherein said third monoclonal antibody reacts with substantially all CD4 bearing cells and said fourth monoclonal antibody reacts with substantially all cells expressing the Leu 8 antigen.
Claim 13
Dependent Claim
31 words
A method in accordance with claim 4 wherein said third monoclonal antibody reacts with substantially all CD4 bearing cells and said fourth monoclonal antibody reacts with substantially all CD8 bearing cells.
Claim 14
Dependent Claim
31 words
A method in accordance with claim 5 wherein said third monoclonal antibody reacts with substantially all CD4 bearing cells and said fourth monoclonal antibody reacts with substantially all CD8 bearing cells.
Claim 15
Dependent Claim
34 words
A method in accordance with claim 4 wherein said third monoclonal antibody reacts with substantially all CD8 bearing cells and said fourth monoclonal antibody reacts with substantially all cells expressing the Leu 7 antigen.
Claim 16
Dependent Claim
34 words
A method in accordance with claim 5 wherein said third monoclonal antibody reacts with substantially all CD8 bearing cells and said fourth monoclonal antibody reacts with substantially all cells expressing the Leu 7 antigen.
Claim 17
Dependent Claim
15 words
A method in accordance with claim 1 wherein said sample is a peripheral blood sample.
Claim 18
Dependent Claim
14 words
A method in accordance with claim 1 wherein the population of interest comprises monocytes.
Claim 19
Dependent Claim
14 words
A method in accordance with claim 1 wherein the population of interest comprises granulocytes.
Claim 20
Dependent Claim
324 words
In a method of identifying and enumerating two or more subpopulations of lymphocytes in a whole blood sample, from which the erythrocytes have been removed, by means of flow cytometry, wherein the sample has been split into three aliquots, wherein the first aliquot is labeled with a first fluorescently labeled monoclonal antibody that reacts with substantially all leukocytes and a second fluorescently labeled monoclonal antibody that reacts with substantially all monocytes, the second aliquot is labeled with a first fluorescently labeled irrelevant control and a second fluorescently labeled irrelevant control, and the third aliquot is labeled with a third fluorescently labeled monoclonal antibody and a fourth fluorescently labeled monoclonal antibody that are different from the first and second monoclonal antibodies and react differentially with the subpopulations of lymphocytes, and wherein the fluorescent label on the first antibody, first control and third antibody are the same and the fluorescent label on the second antibody, second control and fourth antibody are the same but which has an emission spectra different from the other fluorescent label, the improvement comprising the steps of: (a) establishing a lymphocyte gate that will contain the maximum number of all lymphocytes with a minimum level of contamination from other cell populations and debris by analyzing the first aliquot and selecting the gate based upon an analysis of SSC and FL2 to set SSC limit and analysis of FSC and FL1 to set FSC limit and calculating the percentage of contamination of other populations of cells within the gate; (b) establishing fluorescence markers for each of the fluorescence labels used by analyzing the second aliquot applying the gate from step (a) and selecting the markers based upon fluorescence emissions and calculating the percentage of non-specific staining in the sample, and (c) analyzing the third aliquot using the gate and percent contamination from step (a) and the fluorescence markers and percent non-specific staining from step (b) to identify and enumerate cells in each subpopulation.
Claim 21
Dependent Claim
324 words
In a method of identifying and enumerating two or more subpopulations of lymphocytes in a whole blood sample, from which the erythrocytes have been removed, by means of flow cytometry, wherein the sample has been split into three aliquots, wherein the first aliquot is labeled with a first fluorescently labeled monoclonal antibody that reacts with substantially all leukocytes and a second fluorescently labeled monoclonal antibody that reacts with substantially all monocytes, the second aliquot is labeled with a first fluorescently labeled irrelevant control and a second fluorescently labeled irrelevant control, and the third aliquot is labeled with a third fluorescently labeled monoclonal antibody and a fourth fluorescently labeled monoclonal antibody that are different from the first and second monoclonal antibodies and react differentially with the subpopulations of lymphocytes, and wherein the fluorescent label on the first antibody, first control and third antibody are the same and the fluorescent label on the second antibody, second control and fourth antibody are the same but which has an emission spectra different from the other fluorescent label, the improvement comprising the steps of: (a) establishing a lymphocyte gate that will contain the maximum number of all lymphocytes with a minimum level of contamination from other cell populations and debris by analyzing the first aliquot and selecting the gate based upon an analysis of SSC and FL2 to set SSC limit and analysis of FSC and FL1 to set FSC limit and calculating the percentage of contamination of other populations of cells within the gate; (b) establishing fluorescence markers for each of the fluorescence labels used by analyzing the second aliquot applying the gate from step (a) and selecting the markers based upon fluorescence emissions and calculating the percentage of non-specific staining in the sample, and (c) analyzing the third aliquot using the gate and percent contamination from step (a) and the fluorescence markers and percent non-specific staining from step (b) to identify and enumerate cells in each subpopulation.
Claim 22
Dependent Claim
19 words
The method of claim 19 wherein the lymphocyte gate of step (a) includes greater than 98% of all lymphocytes.
Claim 23
Dependent Claim
27 words
A method in accordance with claim 19 wherein said third monoclonal antibody reacts with substantially all T-cells and said fourth monoclonal antibody reacts with substantially all B-cells.
Claim 24
Dependent Claim
32 words
A method in accordance with claim 19 wherein said third monoclonal antibody reacts with substantially all T-cells and said fourth monoclonal antibody reacts with at least one activation antigen expressed by T-cells.
Claim 25
Dependent Claim
34 words
A method in accordance with claim 19 wherein said third monoclonal antibody reacts with substantially all CD4 bearing cells and said fourth monoclonal antibody reacts with substantially all cells expressing the Leu 8 antigen.
Claim 26
Dependent Claim
31 words
A method in accordance with claim 19 wherein said third monoclonal antibody reacts with substantially all CD4 bearing cells and said fourth monoclonal antibody reacts with substantially all CD8 bearing cells.
Claim 27
Dependent Claim
34 words
A method in accordance with claim 19 wherein said third monoclonal antibody reacts with substantially all CD8 bearing cells and said fourth monoclonal antibody reacts with substantially all cells expressing the Leu 7 antigen.
References Cited (Backward Citations)
US3826647A
Cited
US4294817A
Cited
US4284412A
Cited
US4381292A
Cited
US4520110A
Cited
US4657852A
Cited
US4607007A
Cited
US4596035A
Cited
US4599307A
Cited
US4677056A
Cited
US4599304A
Cited
US4767206A
Cited
US4824775A
Cited
US4727020A
Cited
US4810487A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-01-21 | 1994-07-23 | 1995-01-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-01-21 | 1998-07-23 | 1999-01-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-01-21 | 2002-07-23 | 2003-01-22 | $7700.00 | Window Closed / Lapsed |